- Educational inequalities in statin treatment for preventing cardiovascular 1
- 2 disease: cross-sectional analysis of UK Biobank
- 3 Short title: Educational inequalities in statin treatment
- Alice R Carter<sup>1,2\*</sup>, Dipender Gill<sup>3-7</sup>, Richard Morris<sup>2,8</sup>, George Davey Smith<sup>1,2,9</sup>, Amy E Taylor<sup>2,9</sup>, Neil M 4 Davies<sup>1,2,10†</sup>, Laura D Howe<sup>1,2†</sup> 5
  - 1) MRC Integrative Epidemiology Unit, University of Bristol Population Health Sciences, Bristol Medical School, University of Bristol
- 3) Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK 10
- 11 4) Centre for Pharmacology & Therapeutics, Department of Medicine, Hammersmith Campus, 12 Imperial College London, London, UK.
  - 5) Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, UK
  - 6) Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, London, UK
  - 7) Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK
    - 8) Centre for Academic Primary Care, University of Bristol
  - 9) NIHR Bristol Biomedical Research Centre, University of Bristol
- 21 10) K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, 22 NTNU, Norwegian University of Science and Technology, Norway.
- 23 <sup>†</sup>NMD and LDH contributed equally
- 25 **Corresponding author:**
- 26 Ms Alice R Carter
- 27 Oakfield House,
- 28 Oakfield Grove,
- 29 Bristol,

7

8

9

13

14

15

16

17 18

19

20

24

2)

- 30 BS8 2BN
- 31 alice.carter@bristol.ac.uk
- 32 @alicerosecarter
- 33 **Funding**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

No funding body has influenced data collection, analysis or its interpretations. This research was conducted using the UK Biobank Resource using application 10953. ARC is funded by the UK Medical Research Council Integrative Epidemiology Unit, University of Bristol (MC\_UU\_00011/1). ARC, GDS, AET, NMD and LDH work in a unit that receives core funding from the UK Medical Research Council and University of Bristol (MC\_UU\_00011/1). DG is supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. AET and GDS are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at University Hospitals Bristol NHS Foundation and the University of Bristol. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The Economics and Social Research Council support NMD via a Future Research Leaders grant (ES/N000757/1) and a Norwegian Research Council Grant number 295989. LDH is funded by a Career Development Award from the UK Medical Research Council (MR/M020894/1).

#### Disclosures

- DG is employed part-time by Novo Nordisk. The remaining authors have no conflicts of interest to
- 49 declare.

#### **Contributions:**

ARC designed the study, cleaned and analysed the data, interpreted the results, wrote and revised the manuscript. DG advised on defining medications, interpreted the results and critically reviewed and revised the manuscript. RM advised on analyses, interpreted the results and critically reviewed and revised the manuscript. GDS, AET, NMD and LDH all designed the study, interpreted the results, critically reviewed and revised the manuscript and provided supervision for the project. NMD and LDH contributed equally and are joint senior authors on this manuscript. ARC and LDH serve as

57 guarantors of the paper. The corresponding author attests that all listed authors meet authorship 58 criteria and that no others meeting the criteria have been omitted. **Transparency statement:** 59 60 ARC affirms that the manuscript is an honest, accurate and transparent account of the study being 61 reported and no important aspects of the study have been omitted. 62 **Acknowledgements:** 63 This work was carried out using the computational facilities of the Advanced Computing Research 64 Centre - http://www.bris.ac.uk/acrc/ and the Research Data Storage Facility of the University of Bristol - <a href="http://www.bris.ac.uk/acrc/storage/">http://www.bris.ac.uk/acrc/storage/</a>. 65 66 Word count: 4891 67

Abstract

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

Background: The most socioeconomically deprived individuals remain at the greatest risk of cardiovascular disease. Differences in risk adjusted use of statins between educational groups may contribute to these inequalities. We explore whether people with lower levels of educational attainment are less likely to take statins for a given level of cardiovascular risk. Methods and findings: Using data from a large prospective cohort study, UK Biobank, we calculated a QRISK3 cardiovascular risk score for 472 097 eligible participants with complete data on selfreported educational attainment and statin use (55% female; mean age, 56). We used logistic regression to explore the association between i) QRISK3 score and self-report statin use and ii) educational attainment and self-report statin use. We then stratified the association of QRISK3 score, and statin use by strata of educational attainment to test for an interaction. In this sample, greater education was associated with lower statin use, whilst higher cardiovascular risk (assessed by QRISK3 score) was associated with higher statin use in both females and males. There was evidence of an interaction between QRISK3 and education, such that for the same QRISK3 score, people with more education were more likely to report taking statins. For example, in women with 7 years of schooling, equivalent to leaving school with no formal qualifications, a one unit increase in QRISK3 score was associated with a 7% higher odds of statin use (odds ratio (OR) 1.07, 95% CI 1.07, 1.07). In contrast, in women with 20 years of schooling, equivalent to obtaining a degree, a one unit increase in QRISK3 score was associated with an 14% higher odds of statin use (OR 1.14, 95% CI 1.14, 1.15). Comparable ORs in men were 1.04 (95% CI 1.04, 1.05) for men with 7 years of schooling and 1.08 (95% CI 1.08, 1.08) for men with 20 years of schooling. Linkage between UK biobank and primary care data meant we were able to carry out a number of sensitivity analyses to test the robustness of our findings. However, a limitation of our study is that a number of assumptions were made when deriving QRISK3 scores which may overestimate the scores.

- 92 **Conclusions**: For the same level of cardiovascular risk, individuals with lower educational attainment
- 93 are less likely to receive statins, likely contributing to health inequalities.
- 94 Keywords: Inequalities, cardiovascular disease, statins, education, QRISK

# Summary

95

96

99

100

101

102

103

104

105

106

107

108

109

110

- What is already known on this topic?
- Despite reductions in the rates of cardiovascular disease in high income countries,
   individuals who are the most socioeconomically deprived remain at the highest risk.
  - Although intermediate lifestyle and behavioural risk factors explain some of this, much of the effect remains unexplained.

#### What does this study add?

- For the same increase in QRISK3 score, the likelihood of statin use increased more in individuals with high educational attainment compared with individuals with lower educational attainment.
- These results were similar when using UK Biobank to derive QRISK3 scores and when using
  QRISK scores recorded in primary care records, and when using self-reported statin
  prescription data or prescription data from linked primary care records.
- The mechanisms leading to these differences are unknown, but both health seeking behaviours and clinical factors may contribute.

## Introduction

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

Despite reductions in cardiovascular morbidity and mortality in high income countries, the most socioeconomically deprived groups remain at the highest risk of cardiovascular disease (CVD) (1, 2). There is evidence that education is a causal risk factor for CVD (3-5). We have previously demonstrated that part of this association acts through three modifiable risk factors; body mass index (BMI), systolic blood pressure and lifetime smoking behaviour (5). However, as much as 60% of the effect of education on CVD remains unexplained. Previous studies have assessed the association of socioeconomic position (SEP) with primary (prescribed prior to a cardiovascular event) and secondary (prescribed as a result of a cardiovascular event) CVD preventative treatment rates; however, the direction of effect has been mixed (6-10). In an analysis of the Whitehall II cohort study (11), and in the British Regional Heart Study (12) there was no evidence of socioeconomic differences in statin prescribing. In other studies it has been reported that those with lower socioeconomic position are more likely to be prescribed statins (6, 8, 13, 14). Conversely, some studies have found that individuals of lower socioeconomic position are less likely to be prescribed statins (9, 10, 15, 16). One key challenge in trying to unpick the role of education in statin prescribing (or other primary or secondary prevention mechanisms) is that lower education is associated with higher levels of cardiovascular risk factors. For example, lower education is associated with higher BMI, smoking, higher blood pressure, and lower levels of physical activity (5, 17, 18). Therefore, individuals with low education likely have a greater underlying risk of CVD and therefore potentially have a greater need for statins. However, it is possible that educational differences in health-seeking behaviour or interactions between patients and healthcare professionals may result in those with higher educational levels being prescribed preventative medication at a lower level of clinical 'need' (19, 20). Consequently, it is more informative to test whether there are educational differences in statin

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

use dependent upon cardiovascular risk, rather than to look at the crude association of education and statin use. Using the UK Biobank cohort, we investigated whether for a given level of cardiovascular risk, measured using the QRISK3 cardiovascular risk score, people with lower education were less likely to report taking statins as primary prevention than those with higher education (21-23). In secondary analyses we identify whether there are inequalities in the type of statin (Atorvastatin compared with Simvastatin) prescribed, given that Atorvastatin has greater efficacy than Simvastatin but is more costly (24-27). Methods **UK Biobank** The UK Biobank study recruited 503 317 UK adults between 2006 and 2010. Participants attended baseline assessment centres involving questionnaires, interviews, anthropometric, physical and genetic measurements (15, 16). All UK Biobank participants are linked to hospital episode statistic (HES) data, with data available from 1997 in England, 1998 in Wales and 1981 in Scotland (28), with the most recent entry recorded in this analysis in May 2017. Additionally, a subset of participants (approximately 230,000 participants) are linked with primary care data and prescribing data (29). In this analysis, we use data from baseline assessment centres, HES data, and linked primary care data where available. QRISK risk score We created a risk score for cardiovascular disease using the QRISK3 algorithm (23). The QRISK3 score is currently used in primary care systems in England and Wales to define the treatment threshold for statin prescriptions. Current guidelines recommend prescribing statins to individuals with a 10% or greater risk of having a cardiovascular event within 10 years (30, 31). QRISK3 scores were derived for all participants with complete data for educational attainment and reported statin use (N= 472 097)

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

(Supplementary Figure 1). For individuals with missing data in any of the QRISK3 variables multiple imputation was used (see statistical analysis section). Scores were derived according to the publicly available QRISK3 algorithm https://grisk.org/three/index.php. Where measures were recorded in baseline assessment centres, such as BMI, Townsend deprivation score or systolic blood pressure, these values were used. With the exception of systolic blood pressure variability (standard deviation of repeated values) and coronary heart disease in a firstdegree relative under 60 years of age, all QRISK3 variables were available in UK Biobank. In the absence of repeated measures of systolic blood pressure on UK biobank a measure of systolic blood pressure variability was derived from the standard deviation of the two recorded measurements of systolic blood pressure at the baseline assessment centre. A measure of family history of CVD was ascertained from reported heart disease in mothers, fathers and siblings of UK Biobank participants, however age of diagnosis and subtype of CVD, could not be determined. Full details of all variable measurements are available in the supplementary materials. All variables used and assumptions made when deriving QRISK3 scores are available in Supplementary Table 1. UK Biobank treatment codes used to identify cases and ICD9, ICD10 codes and are presented in Supplementary Tables 2 and 3. In a subset of individuals with linked primary care data, QRISK (read 2 code: 38DF.) (N=1 495) (21), or QRISK2 scores (read 2 code: 39DP.) (N = 10 633) (22) were recorded from 2007 onwards. Where more than one QRISK score was recorded for an individual, the first recorded value was used in analysis. Measuring educational attainment UK Biobank participants reported their highest qualification achieved at baseline assessment centres, which was converted to the International Standard Classification for Education (ISCED) coding of years of education (Supplementary Table 4) (32).

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

Measuring statin use Participants were asked about regular medication they were taking, details of which were recorded by UK Biobank study nurses. From this, a primary variable for any reported statin use was generated. The type of statin used (Atorvastatin, Simvastatin, Fluvastatin, Pravastatin and Rosuvastatin) was recorded by study nurses and was used to derive a variable for type of statin. In individuals with linked primary care data, statin prescriptions were recorded in prescription data. In these individuals, a measure of validated statin use was created, defined by a prescription in both the 3 months before and 3 months after baseline. For sensitivity analyses in individuals with a QRISK or QRISK2 score recorded in primary care data, statin use was defined as any statin prescription after a QRISK score was recorded. **Exclusion criteria** Prevalent CVD cases at baseline, who would receive a statin prescription according to NICE guidelines (30, 31, 33, 34), were excluded from analyses. These cardiovascular diagnoses and events were ascertained through linkage to HES data, with cases defined according to ICD-9 and ICD-10 codes (Supplementary Table 3). Individuals were excluded if they had experienced at least one diagnosis of myocardial infarction, angina, stroke, transient ischaemic attack, peripheral arterial disease, type 1 diabetes, chronic kidney disease or familial hypercholesterolaemia (30, 34). The date for each diagnosis is provided in the HES data, which was linked with the date of assessment centre visit provided by UK Biobank. Complete case analyses were carried out on 368 721 individuals, with complete data on age, sex, educational attainment, self-reported statin (medication) use and all variables required for the QRISK3 score (Supplementary Table 1 and Supplementary Figure 1).

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

according to Rubin's rules.

Code and data availability The derived variables have been returned to UK Biobank for archiving. The code used to derive QRISK3 scores and carry out analyses is available at github.com/alicerosecarter/statin\_inequalities. Patient and public involvement Ethical approval for this study was sought from the UK Biobank (project 10953). No patients or participants were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on the interpretation or writing up of results. Statistical analyses To maximise power and potentially reduce bias, multivariable multiple imputation by chained equations (35) was used to impute variables included in the QRISK3 score with missing data, under the missing at random assumption. The sample for imputation was defined as all individuals with complete data on educational attainment and reported statin use. The proportion of missing data ranged from 0% to 15% (see Supplementary Table 5 for full details). In total, 77% of participants had no missing data, 13% of participants were missing data for one QRISK3 variable, 8% of participants were missing data for two QRISK3 variables and 2% of participants were missing data for three, four or five variables. A total of 25 imputed datasets were generated (36). Imputation was carried out separately within strata of years of education and sex to preserve interactions tested in the statistical analyses (37). The mean and standard deviation of continuous variables or proportion and standard error of categorical variables in the imputed data were compared with those from the complete data. All analyses were then carried out in each imputed dataset, with results combined

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

It was determined a priori to carry out all analyses stratified by sex given the known differences in cardiovascular risk profiles for males and females (38, 39), as well as the QRISK3 score being derived separately by sex (23). To confirm the validity of the derived QRISK3 score, a univariable logistic regression model was used to assess the association of the risk score with i) self-reported statin use and ii) incident CVD. We estimated the associations of years of education with i) QRISK3 score (using linear regression) and ii) statin use (using logistic regression). Testing for interaction between QRISK3 score and educational attainment on statin use Logistic regression was used to estimate the association of QRISK3 score with self-reported statin use, stratified by years of education, providing an estimate of interaction on the multiplicative scale (sFigure 2, Route 1). These analyses were not adjusted for any other covariates, assuming all relevant variables are incorporated into the QRISK3 score. Evidence of an interaction between QRISK3 score and years of education was evaluated in a linear model where the interaction term QRISK3×educational attainment was included in the regression model. Secondary analyses To test the hypothesis that there may be educational inequalities in the type of statin prescribed, in individuals who reported using statins to baseline study nurses, we assessed i) whether there was an association of QRISK3 score and years of education independently with self-reported Atorvastatin, which has been suggested to have a greater efficacy, compared with self-reported Simvastatin (baseline) (24-26) and ii) whether there was any evidence of an interaction between QRISK3 score and years of education on type of statin prescribed (sFigure 2, Route 2). Analyses testing the association between QRISK3 and years of education on statin use and statin type independently, as well as for any interaction between QRISK3 score and educational

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272


attainment, on statin use and type of statin prescribed were replicated using complete case data (sFigure 2, Route 3 and 4). To test whether the self-reported statin use data affected the results, we repeated our analysis with statin use defined as a prescription both 3 months before and after baseline from linked primary care prescription data (sFigure 2, Route 5), and also repeated our main analysis with self-reported statin use in the subset of participants with the linked prescription data (sFigure 2, Route 6). In the subsample of primary care individuals with a QRISK or QRISK2 score recorded, analyses were replicated to test for evidence of an interaction between QRISK score and incident statin prescribing. This was defined as any prescription for a statin recorded in primary care data, excluding individuals who reported using statins to study nurses at the baseline assessment centre (sFigure 2, Route 7). QRISK scores were included if they were recorded on or prior to the date of first statin prescription, but consideration was not given to the time between both events. Two further estimates of QRISK3 were derived excluding i) variability of systolic blood pressure and ii) family history of cardiovascular disease from QRISK3 scores. The pairwise correlation between scores with and without these variables was tested. Results **UK Biobank sample** In the main analyses (N = 472 097) 55% of participants were female with a mean age of 56. In females, the QRISK3 score implied a mean 10-year risk of a cardiovascular event of 6.9% (standard deviation (SD) = 5.5). In males, the QRISK3 score implied mean a 10-year risk of a cardiovascular even of 13.1% (SD = 8.4). Participants were more likely to have completed 20 years of education (female = 35%, male = 38%) than 7 years of education (female = 14%, male = 14%). 10% of females and 17% of males reported using statins.

The distribution of variables was similar between the multiply imputed dataset, complete case data, and in the subset of participants with linked primary care data (Supplementary Table 6).

#### Association of QRISK3 score with statins and cardiovascular disease

For a one unit increase in QRISK3 score (i.e. a 1% increase in the 10-year risk of experiencing a cardiovascular event) in females, the odds ratio (OR) for reporting statin use to study nurses was 1.12 (95% confidence interval (CI): 1.12 to 1.13) and the OR for an incident cardiovascular event was 1.12 (95% CI: 1.12 to 1.12) (Figure 1 and Supplementary Table 7). Females with a QRISK3 score of 10 or greater were 1.34 (95% CI: 1.31 to 1.36) times more likely to report using statins than those with a QRISK score of less than 10. In males, the OR for statin use was 1.07 (95% CI: 1.07 to 1.07) and for an incident cardiovascular event the OR was 1.08 (95% CI: 1.08 to 1.08) per unit higher QRISK3 score (Figure 1 and Supplementary Table 7). Males with a QRISK3 score of 10 or greater were 1.49 (95% CI: 1.46 to 1.52) times more likely to report using statins than those with a QRISK score of less than 10.

Figure 1: Odds of self-report statin use per unit increase in baseline QRISK3 score with no education interaction and stratified by years of education in females and males



289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale P value for interaction in females = <0.001 and males = <0.001 Association of education with QRISK3 score and statin prescribing Per year increase in educational attainment was associated with a -0.30 (95% CI: -0.30 to -0.29) reduction in mean QRISK3 score in females and a -0.35 (95% CI: -0.35 to -0.34) reduction in mean QRISK3 score in males (Supplementary Table 8 and Supplementary Figure 3). The prevalence of statin use was highest in those in the lowest strata of educational attainment (equivalent to leaving school after 7 years, with no formal qualifications) (Supplementary Figure 4). Not accounting for cardiovascular risk, each additional year of education was associated with a lower odds of being prescribed statins (all types), (OR in females: 0.93; 95% CI: 0.93 to 0.93, OR in males: 0.96; 95% CI: 0.96 to 0.96) (Supplementary Table 7 and Supplementary Figure 5). Interaction between education and QRISK3 score in relation to statin prescribing In both females and males, there was evidence of an interaction between QRISK3 score and years of education on statin use, such that for the same increase in QRISK3 score, the likelihood of statin use increased more for those of high educational attainment. In females, per unit increase in QRISK3, the OR for reporting statin use in those with the greatest years of education (20 years, equivalent to obtaining a degree) was 1.14 (95% CI: 1.14 to 1.15) compared with an OR of 1.07 (95% CI: 1.07 to 1.07) for those with the least years of education (7 years, equivalent to leaving school with no formal qualifications) (Figure 1). In males, the OR for statin use per unit increase in QRISK3 score in those with 20 years of education was 1.08 (95% CI: 1.08 to 1.08) compared with an OR of 1.04 (95% CI: 1.04 to 1.05) for those with 7 years of education (Figure 1). For both females and males, the P value for interaction was <0.001.

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

Secondary analyses Among individuals prescribed with either atorvastatin or simvastatin, those with higher QRISK3 scores were more likely to have been prescribed the more effective Atorvastatin. The OR for a oneunit higher QRISK3 and reporting Atorvastatin use was, OR: 1.02 (95%CI: 1.02 to 1.03) (Supplementary Table 9). This was similar in males, OR: 1.02 (95% CI: 1.01 to 1.02). Females, but not males, were less likely to have been prescribed Atorvastatin if they had more years of education; e.g. the OR for Atorvastatin prescription for 20 years of education versus 7 years of education was 0.92 in females (95% CI 0.83 to 1.01) and 1.02 in males (95% CI 0.94 to 1.11). There was little evidence of an interaction between QRISK3 score and educational attainment on statin type in females and males (P value for interaction in females = 0.4; P value for interaction in males = 0.9) (Supplementary Figure 6). When analyses were replicated using eligible participants with linked primary care data using i) baseline measures of QRISK3 and self-report statin use, ii) baseline measures of QRISK3 with statin use validated by a prescription and iii) QRISK or QRISK2 score recorded in primary care data with a statin prescription, the evidence for interaction between QRISK3 and educational attainment on statin use remained in females (Figure 2 and Supplementary Figure 7). In males, the interaction between baseline QRISK3 scores and educational attainment on validated prescription remained. However, there was less evidence of an interaction between the primary care recorded QRISK scores and educational attainment on statin prescriptions (P=0.09), although the direction of effect was similar where males with 20 years of education were more likely to be prescribed statins (OR: 1.08; 95% CI: 1.07 to 1.10) than those with 7 years of education (OR: 1.05; 95% CI: 1.03 to 1.08) (Figure 2 and Supplementary Figure 7).

Figure 2: Odds of statin use recorded in primary care prescription data per unit increase in A)

baseline QRISK3 score and B) QRISK or QRISK2 score recorded in primary care, in females and males

				Odds Ratio		N statins
Exposure	Sex	Years of Education		(95% CI)	N	(%)
Baseline QRISK3	Female	No education interaction	•	1.14 (1.13, 1.15)	96 244	2 292 (2)
		7 years	+	1.09 (1.08, 1.10)	14 587	758 (5)
		10 years	-	1.15 (1.13, 1.16)	18 361	435 (2)
		13 years	-	1.16 (1.13, 1.20)	5 553	87 (2)
		15 years	-	1.13 (1.11, 1.15)	12 391	352 (3)
		19 years	<b>-</b>	1.16 (1.14, 1.18)	12 796	242 (2)
		20 years	-	1.16 (1.14, 1.17)	32 556	418 (1)
Baseline QRISK3	Male	No education interaction	•	1.09 (1.09, 1.10)	66 625	3 063 (5)
		7 years	•	1.06 (1.05, 1.07)	9 844	805 (8)
		10 years	•	1.10 (1.09, 1.11)	8 918	413 (5)
		13 years	-	1.09 (1.07, 1.11)	3 367	125 (4)
		15 years	•	1.09 (1.07, 1.10)	6 673	354 (5)
		19 years	•	1.10 (1.09, 1.11)	13 483	595 (4)
		20 years	•	1.10 (1.09, 1.10)	24 340	771 (3)
Primary care QRISK	Female	No education interaction	+	1.12 (1.11, 1.13)	7 338	993 (14)
		7 years	<b>—</b>	1.09 (1.07, 1.11)	1 034	250 (24)
		10 years	<b>—</b>	1.12 (1.10, 1.15)	1 520	203 (13)
		13 years	-	1.14 (1.09, 1.18)	436	57 (13)
		15 years	<b>—</b>	1.09 (1.07, 1.12)	961	124 (13)
		19 years	<del></del>	1.14 (1.11, 1.18)	911	111 (12)
		20 years	<b>—</b>	1.14 (1.12, 1.16)	2 476	248 (10)
Primary care QRISK	Male	No education interaction	•	1.08 (1.07, 1.09)	4 790	912 (19)
		7 years	-	1.05 (1.03, 1.08)	601	166 (28)
		10 years	-	1.08 (1.05, 1.10)	649	114 (18)
		13 years	<b>—</b>	1.09 (1.05, 1.13)	285	42 (15)
		15 years		1.08 (1.05, 1.11)	497	114 (23)
		19 years	-	1.08 (1.06, 1.10)	944	201 (21)
		20 years	-	1.08 (1.07, 1.10)	1814	275 (15)

Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale

Baseline QRISK3: P value for interaction in females = <0.001 and males = <0.001

QRISK score recorded in primary care: P value for interaction in females = 0.034 and males = 0.091

In the complete case sample, there was evidence of an interaction between QRISK3 and education in both males and females considering reported statin use as the outcome, where the P value for interaction was <0.001 for both females and males. However, there was little evidence of an

interaction between QRISK3 and education on statin type (Supplementary Table 10).

Pairwise correlation between the baseline derived QRISK3 score and QRISK3 scores derived excluding i) systolic blood pressure variability estimated from the difference between two baseline

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

measures and ii) self-report of any CVD in a mother, father or sibling, were high (all >0.97) (Supplementary Table 11). Discussion Despite there being a higher prevalence of statin prescribing overall in those with lower levels of education, at a given level of QRISK3 score as a measure of clinical assessment of cardiovascular risk, less educated individuals were less likely to receive statin treatment compared to more highly educated individuals. Results in context Lifestyle and behavioural factors, such as BMI, diet, smoking, risky drinking and exercise have previously been implicated as mediators of the association between education and CVD (17, 18, 40-46). Indeed, the higher overall prevalence of statins in lower educated individuals is likely due to the greater prevalence of these intermediate risk factors, compared with those of greater education (5, 17, 44). However, much of the association between education and CVD remains unexplained. The results presented in this analysis suggest that access to preventative medication for CVD may be contributing to persisting socioeconomic inequalities. It has previously been reported that inequalities exist in favour of those with higher SEP when accessing preventative healthcare (47). In the UK, National Health Service (NHS) health checks are offered to all residents aged between 40 and 74 without pre-existing conditions every 5 years, with the aim of preventing a number of diseases including CVD (such as by calculating QRISK scores), kidney disease and dementia (48). In a recent systematic review by Bunten and colleagues, seven studies were identified that indicated uptake of these health checks is lower in more socioeconomically deprived groups (49). Additionally one study included in this systematic review identified a trend towards lower uptake in smokers; an important risk factor for CVD that is also socially patterned (49, 50). Similar findings were also reported by Wilson and colleagues (51). These

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

reasons for non-uptake of health checks, in combination with the inequalities identified in this study, indicate that methods to improve engagement with NHS health checks and preventative screening methods may reduce inequalities in cardiovascular outcomes. Indeed, differences in health seeking behaviours may be driving some of the inequalities in statin use identified in our study. However, when interaction analyses were repeated using QRISK or QRISK2 scores recorded in primary care data and primary care records of statin prescriptions, these inequalities remained. Therefore, attendance to primary care clinics cannot be the sole driver of these inequalities. The literature is mixed in the direction to which inequalities in access to statins exist, where some studies suggest that individuals with lower socioeconomic position are less likely to be prescribed statins (9, 10, 15, 16) and other studies finding the opposite or no differences (6, 8, 11, 13, 14). Of these previous studies, there was limited consideration for underlying cardiovascular risk in the analyses. Some studies adjusted for cardiovascular comorbidities (8, 13, 15, 16) such as cholesterol level, diabetes status or prevalent cardiovascular events. However, we only identified one other study that comprehensively adjusted for cardiovascular risk (11). Forde and colleagues established risk status via 10-year absolute risk of coronary heart disease determined using the Framingham study (11, 52) and assessed SEP by British civil service grade of employment. In contrast to our results using educational attainment as a measure of SEP, they did not find evidence of inequalities in statin use. The differences in our results compared with Forde and colleagues could be the different measure of SEP used (income vs education) or due to cohort differences, where Forde and colleagues used an occupational cohort study and here, we have used a population-based cohort. Additionally, it has been demonstrated that the QRISK score has a greater predictive power compared with the Framingham score (53). Therefore, our analyses may better account for underlying differences in cardiovascular risk.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

Currently, the QRISK3 scores capture the prevalence of key risk factors in individuals, such as BMI, blood pressure and smoking, but our results show that accounting for these factors alone is not enough to address cardiovascular inequalities. Cardiovascular risk scores may need to be adapted to pay greater attention to SEP; something that has been described previously in the literature (54-56) These risk scores should be in principle, easy to use and clear for clinicians, where it has previously been reported that the use of risk scores in general practice is a source of confusion (57). Despite there being almost 30 000 first instances of statin prescriptions after 1st January 2008 (where QRISK scores were first introduced in 2007), in the primary care data linked with UK Biobank, there were only around 14 000 individuals with a recorded QRISK or QRISK2 scores in the same data. This is higher than in previous research by Finnikin and colleagues, where they identified using primary care records, that only 27% of patients prescribed statins had a recorded QRISK2 score (58). However, the lack of recorded QRISK scores, suggests the decision to prescribe statin treatment may be independent of an objective measure of cardiovascular risk, and potentially prescribed based on more subjective measures by the clinician or the patient. In individuals with linked primary care data, 14% of eligible participants reported using statins to study nurses, however only 3% of participants had a linked prescription in the three months before and after baseline. These individuals without a linked prescription are likely a combination of individuals who are purchasing statins over the counter, have received a prescription from a private clinician, or are no longer prescribed statins. The majority (91%) of those without a linked prescription reported taking Simvastatin (currently the only statin available as an over the counter medicine). Although we cannot definitively discern the reason these individuals did not have a prescription, it is possible that accessing statins through non-NHS GPs (i.e. through private practices) or over the counter is further contributing to inequalities in cardiovascular outcomes. There is, to date, little freely available data on the prevalence of purchasing statins over the counter, rather than

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

via attending a primary care clinic. However, our data suggests it could indeed be highly prevalent in the population. Strengths and limitations The major strength of our work is the large sample size and array of data available. Given the age range of our participants (45-76 years) reported statin use is highly prevalent (10% in females and 17% in males). Additionally, the linked primary care data for 44% of the eligible sample allowed us to i) validate self-reported statin use and ii) compare different mechanisms inequalities may be arising. Where inequalities are present in primary care recorded QRISK scores, inequalities are unlikely to be due to health seeking behaviour and more likely due to factors arising within clinic settings. Conversely, where data is used from UK Biobank baselines assessment, inequalities may be due to either differences in health seeking behaviour (i.e. attending NHS health checks) or factors that arise within the healthcare setting. Lifestyle and behavioural characteristics, which are incorporated in to the QRISK3 score, are likely to be captured much more accurately and completely in UK Biobank compared with a primary care setting. However, there may be some settings where UK Biobank variables may have been measured differently than they would in primary care (59), such as non-fasting blood biomarker measurements. However, the magnitude to which these measurements differ is unlikely to introduce much bias to estimates of the QRISK3 score. Additionally, selection bias is present in UK biobank, where participants are generally of a higher socioeconomic position and healthier than the general population (60). Those who are of a lower socioeconomic position in the UK Biobank potentially differ to those of an equivalent socioeconomic position (or level of educational attainment) in the general population, where UK Biobank participants may be more health conscious and health aware. Therefore, it is possible that the inequalities in the wider population are greater than the inequalities reported here.

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

Despite our large sample size and wealth of data, a number of assumptions were made when generating the QRISK3 scores. For example, in the QRISK3 algorithm (23), the study authors specify medications should be considered if the individual has two or more prescriptions for each class of medication (e.g. corticosteroid or atypical antipsychotic). We were not able to determine the number of prescriptions at baseline and relied on a single self-report measure of medication use. Therefore, medication use may be overestimated in our sample, which would result in an overestimate of the QRISK3 score. Additionally, some measures, such as systolic blood pressure variability and coronary heart disease in a first degree relative under the age of 60, are not available in the UK Biobank data. Although we have included measures likely to capture some of these variables, this may introduce bias to the QRISK3 estimate in UK Biobank compared with a primary care setting. The ISCED definitions of educational attainment (years in schooling) can differ with respect to other measures of socioeconomic position. For example, using ISCED definitions, individuals who left school with a vocational qualification are given a high number of years of schooling (19 years) but will typically go into manual labour jobs. This is likely to explain some of the non-linearities in effects stratified by educational attainment. Clinical implications The results presented here highlight inequalities in statin use by educational attainment. Given the persisting inequalities in CVD, addressing the contribution of differences in statin prescription provides a clear policy target. The two complimentary data sources used in this analysis, UK Biobank baseline data and linked primary care data, indicate two potential mechanisms for these inequalities. Firstly, there are likely to be differences in health seeking behaviour such as in attending NHS health checks as previously evidenced in the literature. Secondly, the inequalities present in the primary care data suggest there are important interactions between the healthcare practitioner and patient that result in unequal prescribing of statins.

Healthcare professionals should consider potential biases in prescribing preventative treatments, or in carrying out risk assessments, such as calculating a QRISK score. Additionally, patient preference for treatment may be socially patterned (61). However, addressing these inequalities requires systemic change and different interventions may be required to address the different mechanisms of inequalities. For example, policy makers and healthcare professionals should consider how they can improve the uptake of NHS health checks, where these risk assessments are carried out, in those who are socioeconomically deprived.

Conclusions

Our analyses demonstrate that at a given level of cardiovascular risk, people with lower levels of educational attainment are less likely to be prescribed statins than people with higher educational attainment, meaning differences in statin prescribing likely contribute to inequalities in

cardiovascular disease. Policies should consider how these inequalities can be minimised.

## References

478

- 479 1. Marmot MG, McDowall ME. Mortality decline and widening social inequalities. Lancet.
- 480 1986;2(8501):274-6.
- 481 2. Bajekal M, Scholes S, O'Flaherty M, Raine R, Norman P, Capewell S. Unequal trends in
- coronary heart disease mortality by socioeconomic circumstances, England 1982-2006: an analytical study. PLoS One. 2013;8(3):e59608.
- Tillmann T, Vaucher J, Okbay A, Pikhart H, Peasey A, Kubinova R, et al. Education and
- coronary heart disease: mendelian randomisation study. BMJ. 2017;358:j3542.
- 486 4. Davies NM, Dickson M, Davey Smith G, van den Berg GJ, Windmeijer F. The causal effects of education on health outcomes in the UK Biobank. Nature Human Behaviour. 2018;2(2):117-25.
- 488 5. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. Understanding the
- consequences of education inequality on cardiovascular disease: mendelian randomisation study.
- 490 BMJ. 2019;365:l1855.
- 491 6. Fleetcroft R, Schofield P, Ashworth M. Variations in statin prescribing for primary
- cardiovascular disease prevention: cross-sectional analysis. BMC Health Serv Res. 2014;14:414.
- 493 7. O'Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary
- 494 prevention of cardiovascular disease: an assessment of differences between countries of the UK and 495 between regions within England. BMJ Open. 2015;5(3):e007207.
- 496 8. Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart. 2005;91(5):630-4.
- 498 9. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, et al. Socioeconomic
- gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol. 2005;60(5):534-42.
- 501 10. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in
- Nottingham general practices: a cross-sectional study. J Public Health Med. 1999;21(1):60-4.
- 503 11. Forde I, Chandola T, Raine R, Marmot MG, Kivimaki M. Socioeconomic and ethnic differences
- in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective
- 505 cohort study. Atherosclerosis. 2011;215(1):223-8.
- 506 12. Ramsay SE, Morris RW, Papacosta O, Lennon LT, Thomas MC, Whincup PH. Secondary
- 507 prevention of coronary heart disease in older British men: extent of inequalities before and after
- implementation of the National Service Framework. J Public Health (Oxf). 2005;27(4):338-43.
- 509 13. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin
- 510 prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and
- Outcomes Framework'. J Public Health (Oxf). 2007;29(1):40-7.
- 512 14. O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary
- 513 prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health
- Improvement Network primary care data. Clin Epidemiol. 2016;8:123-32.
- 515 15. Forsberg PO, Li X, Sundquist K. Neighborhood socioeconomic characteristics and statin
- 516 medication in patients with myocardial infarction: a Swedish nationwide follow-up study. BMC
- 517 Cardiovasc Disord. 2016;16(1):146.
- 518 16. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Kober L, et al. Use of
- 519 statins and beta-blockers after acute myocardial infarction according to income and education. J
- 520 Epidemiol Community Health. 2007;61(12):1091-7.
- 521 17. Mejean C, Droomers M, van der Schouw YT, Sluijs I, Czernichow S, Grobbee DE, et al. The
- 522 contribution of diet and lifestyle to socioeconomic inequalities in cardiovascular morbidity and
- mortality. International Journal of Cardiology. 2013;168(6):5190-5.
- 524 18. Veronesi G, Ferrario MM, Kuulasmaa K, Bobak M, Chambless LE, Salomaa V, et al.
- 525 Educational class inequalities in the incidence of coronary heart disease in Europe. Heart.
- 526 2016;102(12):958-65.

- 527 19. Mitchell AJ, Selmes T. Why don't patients attend their appointments? Maintaining
- 528 engagement with psychiatric services. Advances in Psychiatric Treatment. 2018;13(6):423-34.
- 529 20. Campbell K MA, McCartney G, McCullough S (NHS Health Scotland). Who is least likely to
- attend? An analysis of outpatient appointment 'Did Not Attend' (DNA) data in Scotland. NHS Health
- 531 Scotland; 2015.
- 532 21. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and
- validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective
- open cohort study. BMJ. 2007;335(7611):136.
- 535 22. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting
- 536 cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ.
- 537 2008;336(7659):1475-82.
- 538 23. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction
- algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ.
- 540 2017;357:j2099.
- 541 24. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients
- with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000;5(1):27-32.
- 543 25. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin
- 544 (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol. 2001;87(5):554-9.
- 545 26. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of
- atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
- 547 Am J Cardiol. 2002;89(6):667-71.
- 548 27. Moon JC, Bogle RG. Switching statins. BMJ. 2006;332(7554):1344-5.
- 549 28. Biobank U. Hospital inpatient data.
- 550 <a href="https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/HospitalEpisodeStatistics.pdf">https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/HospitalEpisodeStatistics.pdf</a>; 2019 September
- 551 2019.
- 552 29. Biobank U. Primary Care Linked Data.
- 553 http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/primary care data.pdf; 2019 September 2019.
- 554 30. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification.
- 555 www.nice.org.uk/guidance/cg1812014.
- 556 31. NICE. Cardiovascular risk assessment and lipid modification.
- 557 www.nice.org.uk/guidance/qs1002015.
- 558 32. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. Genome-wide
- association study identifies 74 loci associated with educational attainment. Nature.
- 560 2016;533(7604):539-42.
- 561 33. NICE. Familial hypercholesterolaemia. https://www.nice.org.uk/guidance/qs412013.
- 562 34. NICE. Lipid modification CVD prevention. https://cks.nice.org.uk/lipid-modification-cvd-
- 563 <u>prevention2019</u>.
- 564 35. Royston P. Multiple Imputation of Missing Values. The Stata Journal. 2004;4(3):227-41.
- 565 36. Spratt M, Carpenter J, Sterne JA, Carlin JB, Heron J, Henderson J, et al. Strategies for multiple
- imputation in longitudinal studies. Am J Epidemiol. 2010;172(4):478-87.
- 567 37. Tilling K, Williamson EJ, Spratt M, Sterne JA, Carpenter JR. Appropriate inclusion of
- interactions was needed to avoid bias in multiple imputation. J Clin Epidemiol. 2016;80:107-15.
- 38. Zhao M, Vaartjes I, Graham I, Grobbee D, Spiering W, Klipstein-Grobusch K, et al. Sex
- 570 differences in risk factor management of coronary heart disease across three regions. Heart.
- 571 2017;103(20):1587-94.
- 572 39. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial
- infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247.
- 574 40. Hossin MZ, Koupil I, Falkstedt D. Early life socioeconomic position and mortality from
- 575 cardiovascular diseases: an application of causal mediation analysis in the Stockholm Public Health
- 576 Cohort. BMJ Open. 2019;9(6):e026258.

- 577 41. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, et al. Social
- 578 Determinants of Risk and Outcomes for Cardiovascular Disease A Scientific Statement From the
- 579 American Heart Association. Circulation. 2015;132(9):873-98.
- 580 42. Nordahl H, Rod NH, Frederiksen BL, Andersen I, Lange T, Diderichsen F, et al. Education and
- risk of coronary heart disease: assessment of mediation by behavioral risk factors using the additive
- 582 hazards model. Eur J Epidemiol. 2013;28(2):149-57.
- 583 43. Degano IR, Marrugat J, Grau M, Salvador-Gonzalez B, Ramos R, Zamora A, et al. The
- association between education and cardiovascular disease incidence is mediated by hypertension,
- 585 diabetes, and body mass index. Sci Rep. 2017;7(1):12370.
- 586 44. Kershaw KN, Droomers M, Robinson WR, Carnethon MR, Daviglus ML, Monique Verschuren
- 587 WM. Quantifying the contributions of behavioral and biological risk factors to socioeconomic
- 588 disparities in coronary heart disease incidence: the MORGEN study. Eur J Epidemiol.
- 589 2013;28(10):807-14.
- 590 45. van Oort FVA, van Lenthe FJ, Mackenbach JP. Material, psychosocial, and behavioural factors
- 591 in the explanation of educational inequalities in mortality in the Netherlands. J Epidemiol Commun
- 592 H. 2005;59(3):214-20.
- 593 46. Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT. Do cardiovascular risk factors
- 594 explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular
- mortality, and acute myocardial infarction? American Journal of Epidemiology. 1996;144(10):934-42.
- 596 47. Cookson R, Propper C, Asaria M, Raine R. Socio-Economic Inequalities in Health Care in
- 597 England. Fisc Stud. 2016;37(3-4):371-403.
- 598 48. England PH. Using the world leading NHS Health Check programme to prevent CVD
- 599 <a href="https://www.gov.uk/government/publications/using-the-nhs-health-check-programme-to-prevent-">https://www.gov.uk/government/publications/using-the-nhs-health-check-programme-to-prevent-</a>
- 600 cvd/using-the-world-leading-nhs-health-check-programme-to-prevent-cvd2018 [updated
- 601 24/01/2018. Available from: <a href="https://www.gov.uk/government/publications/using-the-nhs-health-">https://www.gov.uk/government/publications/using-the-nhs-health-</a>
- 602 <u>check-programme-to-prevent-cvd/using-the-world-leading-nhs-health-check-programme-to-</u>
- 603 prevent-cvd.
- 604 49. Bunten A, Porter L, Gold N, Bogle V. A systematic review of factors influencing NHS health
- check uptake: invitation methods, patient characteristics, and the impact of interventions. BMC
- 606 Public Health. 2020;20(1):93.
- 50. Dalton AR, Bottle A, Okoro C, Majeed A, Millett C. Uptake of the NHS Health Checks
- 608 programme in a deprived, culturally diverse setting: cross-sectional study. J Public Health (Oxf).
- 609 2011;33(3):422-9.
- 610 51. Wilson R, Kuh D, Stafford M. Variations of health check attendance in later life: results from
- a British birth cohort study. BMC Public Health. 2019;19(1):1518.
- 612 52. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General
- 613 cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation.
- 614 2008;117(6):743-53.
- 615 53. Collins GS, Altman DG. An independent external validation and evaluation of QRISK
- cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009;339:b2584.
- 617 54. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of
- the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract.
- 619 2005;55(520):838-45.
- 620 55. Tunstall-Pedoe H, Woodward M, estimation Sgor. By neglecting deprivation, cardiovascular
- risk scoring will exacerbate social gradients in disease. Heart. 2006;92(3):307-10.
- 622 56. Woodward M, Brindle P, Tunstall-Pedoe H, estimation Sgor. Adding social deprivation and
- family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health
- 624 Extended Cohort (SHHEC). Heart. 2007;93(2):172-6.
- 625 57. Liew SM, Blacklock C, Hislop J, Glasziou P, Mant D. Cardiovascular risk scores: qualitative
- 626 study of how primary care practitioners understand and use them. Br J Gen Pract.
- 627 2013;63(611):e401-7.

- 628 58. Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice: a
- 629 THIN database study. Br J Gen Pract. 2017;67(665):e881-e7.
- 630 59. Elliott P, Peakman TC, Biobank UK. The UK Biobank sample handling and storage protocol for
- the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37(2):234-
- 632 44.

- 633 60. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
- 634 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the
- 635 General Population. Am J Epidemiol. 2017;186(9):1026-34.
- 636 61. Schroder SL, Fink A, Richter M. Socioeconomic differences in experiences with treatment of
- coronary heart disease: a qualitative study from the perspective of elderly patients. BMJ Open.
- 638 2018;8(11):e024151.